Aclarubicin
Top View
- Combination of Aclarubicin and Etoposide for the Treatment of Advanced Acute Myeloid Leukemia: Results of a Prospective Multicenter Phase II Trial
- Molecular Effects of Topoisomerase II Inhibitors in AML Cell Lines
- A Meta-Analysis of CAG (Cytarabine, Aclarubicin, G-CSF)
- Mechanism Mediated by a Noncoding RNA, Nc886, in the Cytotoxicity of a DNA-Reactive Compound
- Guidelines on Treatment of Extravasation with Cytotoxic Drugs
- TOP2A Is Overexpressed and Is a Therapeutic Target for Adrenocortical Carcinoma
- Combination of Decitabine, Idarubicin, Cytarabine, and G-CSF (DIAG) Regimen for the Treatment of High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Molecular Blueprints for Antitumor Drugs
- Fast and Complete Removal of the 5
- Auspar Attachment 2: Extract from the Clinical Evaluation Report For
- Chemotherapy-Related Leiomyopathy: a Suggested Morphological Explanation for the Intestinal Dysmotility Affecting Patients Treated with Anthracyclines
- An in Vivo and in Vitro Trial of Aclarubicin in Metastatic Breast Cancer: a Novel Approach to the Study of Analogs
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Isolation, Drug Sensitivity, and Some Biochemical and Genetical Properties of Macromomycin-Resistant Mouse Lymphoblastoma L5178y Cells
- Synergistic Antitumor Activity of Oridonin and Arsenic Trioxide on Hepatocellular Carcinoma Cells
- Savene, INN-Dexrazoxane
- Patent Application Publication ( 10) Pub
- Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in The